Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics submitted an IND application to the FDA to evaluate EIK1006, a novel androgen receptor antagonist, for advanced metastatic prostate cancer. EIK1006 is structurally unrelated to existing lutamide-class antagonists and was optimized against wild-type and clinically relevant AR variants using Eikon's single-molecule imaging platform.
Key figures
- Drug Name
- EIK1006
- Phase Of Trial
- IND (pre-Phase 1)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.